

Hafnia Alvei Urinary Tract Infection

Jamela Ghadban Auda Al-Grawi

ABSTRACT:

BACKGROUND:

The genus *Hafnia*, a member of the family Enterobacteriaceae, consists of Gram negative bacteria that are occasionally implicated in both intestinal and extraintestinal infections in human. This genus contains only a single species (*Hafnia alvei*).

METHODS:

The above bacterium was identified from 250 bacterial strains which were isolated from 220 urine samples of patients with urinary tract infection.

RESULTS:

One *H. alvei* strain was isolated from an elderly patient, and identified by conventional biochemical tests and API20E system at the first time in Iraq. Antimicrobial susceptibility test showed that this strain is sensitive to Cefotaxime, Ciproflaxacin, Chloramphenicol, Doxycycline and Trimethoprim-sulfamethazole, while it is resistant to Penicillin, Oxacillin and Amoxicillin plus clavulanic acid.

CONCLUSION:

H. alvei an important uropathogen that causing urinary tract infection in elderly and may be in immunocompromised patients.

KEY WORDS: *Hafnia alvei*, urinary tract infections

INTRODUCTION:

The genus *Hafnia* is one of more than 40 genera that currently comprise the family Enterobacteriaceae. Møller originally described this genus in 1954 and he suggested *Hafnia alvei* as the name of the species⁽¹⁾. The specific epithet in the name *H. alvei* is derived from the Latin noun *alveus* meaning beehive, with "alvi" meaning "of a beehive" because these bacteria had something to do with bees or beehives although they did not⁽²⁾. However, *H. alvei* has been recovered on occasion from the intestines of honeybees as well as from honey⁽³⁾. The genus name *Hafnia* is the historical name (Havn) for the city of Copenhagen, Denmark⁽⁴⁾.

Most standard microbiology texts list mammals, birds, reptiles, fish, soil, water, sewage and foods as sources from which *hafniae* can be recovered^(5,6). Food products commonly yield *hafniae*, meat, pork products, milk and milk products and freshwater fish, harbor *H. alvei*^(7,8,9). Over the past quarter of a century, there have been few studies that have systemically looked at the role of these bacteria⁽¹⁰⁾. There are two well-described outbreaks of *H. alvei* infection associated with the poultry industry^(11,12). This bacterium is an uncommon human pathogen but it causes nosocomial and community-acquired infections⁽¹³⁾. Moreover, *H. alvei* recovered from oropharyngeal

specimens, from the gastrointestinal tract, less often from blood and variety of other anatomic sites, including tissue, urine and catheters^(14,15). *H. alvei* can cause infection via a nosocomial route⁽¹⁵⁾ associated with gastrointestinal disease⁽¹⁶⁾, illnesses associated with wounds/abscesses, respiratory tract infections, including pneumonia⁽¹⁷⁾, broncopneumonia⁽¹⁵⁾, hepatic abscess, cholecystitis^(18,19), muscle abscess⁽²⁰⁾, septic arthritis⁽²¹⁾, cervicovaginitis⁽²²⁾, and bacteremia seeded from the genitourinary tract⁽²³⁾ with majority cases occur in males (71%).

H. alvei have been isolated from community-acquired urinary tract infection and hemolytic uremic syndrome cases^(24,25), also from hospital-acquired urinary tract case in intensive care unit (10). This bacterium causes urinary tract infection and sepsis in infants⁽²⁶⁾. A laboratory surveillance study showed that the most common focus of *H. alvei* isolation as nosocomial infection was urinary tract infection (81% of *H. alvei*)⁽²⁷⁾.

There is only a limited number of data presently available on disease states associated with this bacterium, so the aim of this study focused on isolation of *H. alvei* from urine samples. Very little is known about these organisms in regard to the role(s) they may play as human pathogens in general or urinary tract pathogens in specific.

Department, Al-Kindy College of Medicine,
University of Baghdad.

HAFNIA ALVEI INFECTION

PATIENTS AND METHODS:

PATIENTS:

This study included 220 patients suffering from urinary tract infection (200 hospitalized patients and 20 outpatients, comprises all age groups and both gender) admitted to Al-Kindy Teaching Hospital, during 2 years (between January 2004 and December 2006).

Urine Samples: A mid-stream urine sample was collected from all patients and cultured on blood and MacConkey's agar plates for 24-48 hours at 37°C.

Conventional Biochemical Tests: All bacterial isolates were examined morphologically by Gram's stain and subjected to by some biochemical testes including: oxidase test, catalase test, IMVC tests, gas and H₂S production, motility test, urease test, gelatinase test and the ability to grow in KCN (28, 29).

API20E System: The bacterial isolates suspected as Hafnia according to conventional biochemical tests results were re-examined by API20E system (BioMerieux Vitek, Inc.).

Antibiotic Susceptibility Test: *H. alvei* antimicrobial susceptibility was tested against the following antibiotics: Penicillin (10µg), Oxacillin (1µg), Amoxicillin plus clavulanic acid (20/10µg), Chloramphenicol (30 µg), Trimethoprim-sulfamethaxazole (5µg), Ciprofloxacin (5µg), Doxycycline (30µg), and Cefotaxime (30µg)(28,29, 30).

RESULTES AND DISCUSION:

A total of 250 bacterial isolates recorded from 220 urinary tract infected patients. The suspected Hafnia isolates according to the colony morphology on blood and MacConky's agars, Gram's stain and the results of conventional tests (Table-1), were also examined by API20E system. The colony morphology of *H. alvei* on MacConky's agar appears as large, smooth, convex, either pink or translucent colony of 2-3 mm in diameter with an entire edge (31, 32). *H. alvei* are Gram negative rods when stained by Gram' stain and examined under light microscope.

Table-1: Conventional biochemical tests results of *H. alvei* suspected strains.

Tests	Results
Lactose fermentation	- or+
Oxidase	-
Catalase	+
Motility	+
Indole	-
Citrate utilization	- or+
Methyl red	- or+
Vogus Proskuar	- or+
Acid/Gas from glucose	+/- or +/+
Urease	-
Gelatinase	-
Growth in KCN	+
H ₂ S in TSI	-

The resultes revealed in Table-1 showed that there is general agreement with the previous studies. The genus Hafnia consists of strains that conform to general characteristics, being Gram-negative, peritrichously flagellated rods that are oxidase negative, catalase positive and nonsporulating.

They are facultatively anaerobes, producing acid with or without gas from the metabolism of D-glucose, indole negative, most strain are VogusProskaur test positive, methyl red positive, while invariably H₂S negative in TSI, and are motile (5).

HAFNIA ALVEI INFECTION

After examining suspected Hafnia isolates by API20E system only one bacterial isolate originally identified as *H. alvei* showed pattern results revealed in Table-2. There was an agreement

between conventional biochemical tests and API20E system results, and recorded character trails in Bergey's Manual of Systematic Bacteriology (4).

Table-2: API20E system results of *H. alvei* strain isolated from urinary tract infected patient.

Tests	Results	Tests	Results
ONPG	+	MAN	+
ADH	-	INO	-
LDC	+	SOR	-
ODC	+	RHA	-
CIT	-	SAC	-
H ₂ S	-	MEL	-
URE	-	AMY	-
TDA	-	ARA	+
IND	-	OX	-
VP	-	NO ₃ -NO ₂	+
GEL	-	MOB	+
GLU	+	McC	+
		OF-F	+
		OF-O	+

H. alvei strain obtained in this study, was isolated from urine sample of a 60-year old man suffering urinary tract infection, the above isolate gave heavy and pure growth on MacConky's agar and this finding agree with previous study showed that *H. alvei* can be isolated from urine of a community-based patient and elderly are at highest risk⁽²⁷⁾.

The antimicrobial susceptibility test results of *H. alvei* isolated strain are presented in Table(3),

showed that this bacterium was sensitive to Cefotaxime, Ciprofloxacin, Chloramphenicol, Doxycycline and Trimethoprim-sulfamethaxazole, while it is resistant to Penicillin, Oxacillin and Amoxicillin plus clavulanic acid. Many studies on *H. alvei* antimicrobial susceptibility showed the same results obtained in this investigation^(10, 27, 33). The resistance of *H. alvei* may be due to the producing β -lactamases, so that this bacterium is resistant to some Penicillins^(34, 35, 36).

Table-3: Antimicrobial susceptibility tests results of *H. alvei* strain isolated from urine of patient with urinary tract infection, R: Resistant; S: Sensitive.

Antibiotics	Results
Cefotaxime(30 μ g)	S
Ciprofloxacin(5 μ g)	S
Chloramphenicol(30 μ g)	S
Doxycycline(30 μ g)	S
Trimethoprim-sulfomethaxazole(5 μ g)	S
Penicillin(10 μ g)	R
Oxacillin(1 μ g)	R
Amoxicillin plus Clavulanic acid(20/10 μ g)	R

CONCLUSION:

The present investigation recorded and for the first time the isolation and identification of *H. alvei* from urinary tract infection in Iraq. The possibility of an extraintestinal invasive infection such as urinary tract infections, bacteremia or pneumonia caused by *H. alvei* should be taken into account in elderly, immunocompromized patients and even infants. There are many unanswered questions regarding this genus. Clearly, the most important issue concerns the frequency and type of human infections associated with *H. alvei*.

H. alvei is usually considered as moderately or nonpathogenic for humans. However, recent descriptions of severe community or nosocomial infections due to *H. alvei* have challenged this belief. The actual role of *H. alvei* in human disease remains to be defined.

REFERENCES:

1. Møller, V. 1954. Distribution of amino acid decarboxylases in Enterobacteriaceae. *Acta Pathol. Microbiol. Scand.* 35:259-277. (Medline)
2. Ewing, W. H. 1986. Identification of Enterobacteriaceae. Elsevier, New York, N.Y.
3. Salimov, R. M. 1978. Study of the *Hafnia* isolated from honey. *Veterinariia* 1978(April):44-46. (In Russian/Abstract.)
4. Sakazaki, R. 1984. *Hafnia*, p. 484-486. In N. R. Krieg, and J. G. Holt (ed.), *Bergey's manual of systematic bacteriology*, vol. 1. Williams & Wilkins, Baltimore, Md.
5. Farmer, J. J., III. 2003. Enterobacteriaceae: introduction and identification, p. 636-653. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. A. Pfaller, and R. H. Tenover (ed.), *Manual of clinical microbiology*, 8th ed. ASM Press, Washington, D.C.
6. Farmer, J. J., III, B. R. Davis, F. W. Hickman-Brenner, et al . 1985. Biochemical identification of new species and biogroups of Enterobacteriaceae isolated from clinical specimens. *J. Clin. Microbiol.* 21:46-76.
7. Gamage, S. D., J. B. Luchansky, and S. C. Ingram. 1998. Pulsed-field gel electrophoresis typing of *Hafnia alvei* isolated from chub-packed and retail ground beef. *Lett. Appl. Microbiol.* 26:105-109.
8. Lindberg, A.-M., Å. Ljungh, S. Ahrné, et al . 1998. Enterobacteriaceae found in high numbers in fish, minced meat and pasteurized milk or cream and the presence of toxin encoding genes. *Int. J. Food Microbiol.* 39:11-17.
9. Ridell, J., and H. Korkeala. 1997. Minimum growth temperatures of *Hafnia alvei* and other Enterobacteriaceae isolated from refrigerated meat determined with a temperature gradient incubator. *Int. J. Food Microbiol.* 35:287-292.
10. Janda, J. M., and S. L. Abbott. 2006. The genus *Hafnia*: from soup to nuts. *Clin. Microbiol. Rev.* 19:12-18.
11. Proietti, P. C., F. Passamonti, M. P. Franciosi, et al . 2004. *Hafnia alvei* infection in pullets in Italy. *Avian Pathol.* 33:200-204.
12. Real, F., A. Fernández, F. Acosta, et al . 1997. Septicemia associated with *Hafnia alvei* in laying hens. *Avian Dis.* 41:741-747.
13. Günthard, H., and A. Pennekamp. 1996. Clinical significance of extraintestinal *Hafnia alvei* isolates from 61 patients and review of the literature. *Clin. Infect. Dis.* 22:1040-1045.
14. Washington, J. A., II, R. J. Birk, and R. E. Ritts, Jr. 1971. Bacteriologic and epidemiologic characteristics of *Enterobacter hafniae* and *Enterobacter liquefaciens*. *J. Infect. Dis.* 124:379-386.
15. Ratnam, S., R. W. Butler, S. March, et al . 1979. *Enterobacter hafniae*—Newfoundland. *Can. Dis. Wkly. Rep.* 5:231-232.
16. Redonodo, J., E. Maseda, A. Riquelme, et al . 2005. *Hafnia alvei* in a rare case of severe pneumonia in a postanesthesia recovery unit. *Rev. Esp. Anestesiología y Reanimación.* 52:359-62. (Abstract.)
17. Barry, J. W., E. A. Dominguez, D. J. Boken, et al . 1997. *Hafnia alvei* infection after liver transplantation. *Clin. Infect. Dis.* 24:1263-1264.
18. Wiström, J., T. Myrnäs, C. Lundgren, et al . 1998. A case of acute cholecystitis due to *Aeromonas sobria* and *Hafnia alvei* from northern Europe. *Clin. Microbiol. Infect.* 4:607-609.
19. Pulcini, C., S. Roth, E. Bernard, et al . 2003. *Hafnia alvei* bacteremia with liver and muscle abscess: a case report. *Presse. Med.* 32:1026-7. (In French/Abstract).
20. Lutz, B., R. Ratard, D. Dodson, et al . 2001. Septic arthritis following anterior cruciate ligament reconstruction using tendon allografts—Florida and Louisiana, 2000. *Morb. Mortal. Wkly. Rep.* 50:1081-1083.
21. Ozturk, C. E., I. Ozdemir, T. Yavuz, et al . 2006. Etiologic agents of cervicovaginitis in Turkish women. *Saudi Med. J.* 27:1503-7.

HAFNIA ALVEI INFECTION

22. Englund, G. W. 1969. Persistent septicemia due to *Hafnia alvei*. *Am. J. Clin. Pathol.* 51:717-719.
23. Andronova, N. I. 1978. Characteristics of the enterobacteria strains isolated from the urine in urinary tract infections. *Zh. Mikrobiol. Epidemiol. Immunobiol.* 12:55-9. (In Russian/Abstract).
24. Crandall, C., S. L. Abbott, Y. Q. Zhao, et al . 2006. Isolation of toxigenic *Hafnia alvei* from a probable case of hemolytic uremic syndrome. *Infection.* 34:227-9.
25. Liu, C. H., W. J. Lin, C. C. Wang, et al . Young-infant sepsis combined with urinary tract infection due to *Hafnia alvei*. *J. Formos. Med. Assoc.* 106(3Suppl):S39-43.
26. Laupland, K. B., D. L. Church, T. Ross, et al . 2006. Population-based laboratory surveillance of *Hafnia alvei* isolation in a Canadian health region. *Ann. Clin. Microbiol. Antimicrob.* 18:12.
27. Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial disk susceptibility tests. Approved standard, 9th ed. Performance standards for antimicrobial susceptibility testing; 16th informational supplement, 7th ed. Clinical and Laboratory Standards Institute, Wayne, Pa..
28. Collee, J. G., R. S. Miles, and B. Watt. 1996. Test for the identification of bacteria. In: Macki and McCartney Practical Medical Microbiology. Cruickshank, R., J. G. Collee, B. P. Marmion, and A. Simmons. 14th ed. Vol.1, Churchill Livingstone, New York, pp. 133-49.
29. Physicians Genrx. 1996. The Complete Drug Reference. Mosby-Yearbook.
30. Sakazaki, R. 2005. Genus *Hafnia* Møller 1954, p. 681-685. In D. Brenner, N. Krieg, J. T. Staley, and G. Garrity (ed.), *Bergey's manual of systematic bacteriology*, 2nd ed. Springer, New York, N.Y.
31. Sakazaki, R., and K. Tamura. 1991. The genus *Hafnia*, p. 2816-2821. In A. Balows, H. G. Trüper, M. Dworkin, W. Harder, and K.-H. Schleifer (ed.), *The prokaryotes: a handbook on the biology of bacteria ecophysiology, isolation, and identification, applications.* Springer-Verlag, Berlin, Germany.
32. Stock, I., M. Rahman, K. J. Sherwood, et al . 2005. Natural antibiotic susceptibility patterns and biochemical identification of *Escherichia albertii* and *Hafnia alvei* strains. *Diagn. Microbiol. Infect. Dis.* 51:151-163.
33. Girlich, D., T. Naas, S. Bellais, et al . 2000. Heterogeneity of AmpC cephalosporinases of *Hafnia alvei* clinical isolates expressing inducible or constitutive ceftazidime resistance phenotypes. *Antimicrob. Agents Chemother.* 44:3220-3223.
34. Piddock, L. J. V., R. N. Walters, Y.-F. Jin, et al . 1997. Prevalence and mechanism of resistance to 'third-generation' cephalosporins in clinically relevant isolates of Enterobacteriaceae from 43 hospitals in the UK, 1990-1991. *J. Antimicrob. Chemother.* 39:177-187.
35. Thomson, K. S., C. C. Sanders, and J. A. Washington II. 1993. Ceftazidime resistance in *Hafnia alvei*. *Antimicrob. Agents Chemother.* 37:1375-1376.